Amivantamab + Lazertinib in EGFR-Mutated Advanced NSCLC: PALOMA-2 Update
Intravenous amivantamab plus lazertinib is already an established first-line option for patients with EGFR-mutated advanced NSCLC, based on the phase III MARIPOSA study.
Intravenous amivantamab plus lazertinib is already an established first-line option for patients with EGFR-mutated advanced NSCLC, based on the phase III MARIPOSA study.
